Research programme: cancer therapeutics - Crescendo Therapeutics/Takeda

Drug Profile

Research programme: cancer therapeutics - Crescendo Therapeutics/Takeda

Alternative Names: Humabody® drug conjugates - Crescendo Biologics/Takeda

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Crescendo Biologics
  • Developer Crescendo Biologics; Takeda Oncology
  • Class Antineoplastics; Drug conjugates; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Oct 2016 Crescendo Biologics and Takeda enter into a collaboration and licensing agreement to develop and commercialise Humabody®-based therapeutics for the treatment of Cancer
  • 10 Oct 2016 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top